



		1
9.	<section-header><section-header><section-header><section-header><image/><image/><image/></section-header></section-header></section-header></section-header>	Now, let's talk about muscle involvement heterogeneity. Again, our focus here is late-onset. So if you look at the literature, about 25% to 30% of symptomatic adult cases can have a normal muscle biopsy. Again, recall where this biopsy was taken. But if you see to the left, there's a lot of heterogeneity within the individual muscle fibers, and then you can have completely normal muscle, which is to the bottom right. And then if you look at EM, this fiber variability is even seen at the level of EM, completely normal, surrounded by completely involved muscle fiber.
10.	<section-header><section-header>Pathophysiology After ER5e. some or division of the muscle bission$0 = 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 +$</section-header></section-header>	So I think we've learned a lot in the space of enzyme therapy, what you and where you start is where you end up. So if someone has started at just under 6 months of age, you can see that after enzyme therapy, there's still significant glycogen accumulation in this quadriceps muscle biopsy. If someone is treated at less than 3 months of age, this is the case with infantile Pompe. So these are just learning examples. You can almost see a dimorphic response with some very healthy looking muscles and some very involved muscle fibers. And then when you start at less than 1 month—which is really the goal of newborn screening—you can see very clean muscle fibers after the initiation of enzyme therapy. So this is one story that we've learned.
11.	<section-header><section-header><section-header></section-header></section-header></section-header>	Then, through brilliant work from Nina Raben, we've learned the role of defective autophagy and autophagic buildup, which can also occur right in the newborn screening setting with muscle biopsies for patients with LOPD telling us that the disease pathology is starting early, we know that there's downstream mitochondrial involvement and abnormalities.
12.	<section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header>	And now what we are also learning is, is there glycogen buildup and a pathophysiology occurring outside of the muscle fiber. And by this, I mean the endomysium, which is that thin layer of connective tissue containing vessels and nerves. And the key here is blood vessels surrounding each muscle fiber. Remember that we are dependent on enzyme therapy delivery through these capillaries and blood vessels. And so now, if you look to the right, what you're going to see is very healthy looking muscle. And there, there's very good glycogen clearance.




Integrating New Therapies, Whole-Person Markers for Disease Monitoring, and Shared Decision-making Into Practice




Priya S. Kishnani, MD, MBSS, Mark Roberts, BSc, MBChB, FRCP, MD, Dr. med. Benedikt Schoser, FEAN English

Integrating New Therapies, Whole-Person Markers for Disease Monitoring, and Shared Decision-making Into Practice





Priya S. Kishnani, MD, MBSS, Mark Roberts, BSc, MBChB, FRCP, MD, Dr. med. Benedikt Schoser, FEAN English


25.	Quantitative Muscle Ultrasound and Electrical Myography in LOPD: A Pilot Study of Reliability, Longitudinal Change and Correlation With Function • Patients had received ERT for 4.2 ± 2 years on average • Muscle thickness: • Deltoid, biceps brachli and forearm flexors has significant baseline values and demonstrated significant changes over the study period • Subcutaneous fat: • No change at 12 or 24 months in any muscle sampled • Muscle EI: • No change at 12 or 24 months in any muscle sampled • Muscle EI: • A taseline: high echointensity (>50) for all tested muscles: deltoid, biceps brachli, triceps brachli, forearm flexors, vastus lateralis, tiblails anterior • Stable in all muscles except vastus lateralis • The vastus lateralis El was 77.1 at baseline, 84.5 at 12 months and 97.7 at 24 months • At 24 months was increased 27% form baseline	And so now let's go to something that could be used more at the bedside and quicker. This is muscle ultrasound. Quantitative muscle ultrasound. Our group had published earlier about the role of quantitative muscle ultrasound in patients with LOPD, adults with LOPD. And we showed it as a response marker to enzyme therapy.
26.	 Duscle Ultrasound in Patients With LOPD Identified by Discussion Outrasound used to measure echo intensity Most affected muscles: quadriceps and medial gastrocnemius Elevations also seen in thoracic paraspinal muscles Most frequently affected in upper extremity: biceps brachit Echo intensity scores correlated with increasing CK levels Utility of non-invasive imaging to assess and monitor 	So now can we apply this to the newborn screening setting? What we were very surprised to see, but not really a surprise, I should say, is that when you look at it, the affected muscles are really falling into the same group as we are seeing in adults with LOPD. And so we are seeing that this is early on, when functionally, these children are doing extremely well. And also, we found a correlation of this with increasing CK levels. And so I think it's important for us to think about using some of these non-invasive imaging markers to monitor and evaluate our patients.
27.	 The New Era of LOPD Management New emerging phenotype of patients with LOPD Increased surveillance allows for early intervention T is critical to identifying the earliest signs of disease progression Kinematic analysis of posture and movement (in NBS setting) Assessment of motor status (function, strength) Comprehensive ongoing analyses (pulmonary, musculoskeletal, biomarkers, including urine hex4, clinical, patient-reported outcomes) allows for understanding disease burden Imaging: whole body MRI and muscle ultrasound are emerging assessment tools of disease severity and progression 	And so today, I really want to leave us on this note that we are in a new era of diagnosis, of management. There's a new emerging phenotype, increased surveillance. I'm not saying to over-medicalize, but also do not lose sight of some of these children. The physical therapist is your best friend. Comprehensive analysis with a multidisciplined team approach, the use of different biomarkers as available at your center, and also the role of imaging modalities. Thank you.
28.	<section-header><section-header><section-header></section-header></section-header></section-header>	And with that, I'm going to turn this over to Dr. Roberts. Thank you very much, Priya. Very comprehensive review of the pathophysiology. But our excitement about the condition is that it's treatable, a rare thing to say in neuromuscular and even in metabolic disorders.





		 to the licensing of the treatment and has been available now for many years, and certainly has been the standard of care, in fact, since 2006. NOTES: This is a Kaplan-Meier curve illustrating survival at 18 months of age in the 1602 study On the x-axis is the age of the patient in months; on the y-axis is the proportion of patients alive The blue line represents the 18 patients in trial 1602 and the purple line represents the untreated historical comparator cohort All 18 patients on treatment were alive at 18 months of age compared with 1 of the 62 patients in the untreated historical give significant prolongation of survival at 18 months of age
31.	<section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></section-header></section-header></section-header>	The FDA did, of course, recommend that there should be a placebo-controlled trial in adults and children with LOPD, not least, of course, because of the profound heterogeneity of the condition. And this was the late-onset treatment study that you'll remember. This was a randomized, double-blinded study against placebo. There were 100 patients in this followed up for 1 year, and there was a useful co-primary endpoint looking both at motoric abilities—the 6-minute walk test or 6MWT, which also, of course, looks not just at motor function, but exercise tolerance—and then there's a respiratory metric, the forced vital capacity or FVC. And it was quite clear that there was a sustained improvement in these patients after an early improvement over the first 6 months, maintained out over the primary analysis period of 78 weeks. So this looks very encouraging, always with metrics. And of course, as people such as Ken Berger in the audience will agree, assessing FVC isn't always easy. So it's helpful to support this with other measurements. And certainly the maximal inspiratory pressure and expiratory pressure, useful to look at diaphragm and intercostal function as well, supported that data on the FVC, and looks so encouraging. NOTES: Pulmonary function tests have been used to clinically monitor the response of


















 So it's a patient living with Pompe disease now for at least 30 years, and I got to know here. I also like to think arefully a biolog-term to think arefully a biolog-term to the set of the careful y a biolog-term to the set of th	 So it's a patient for al least of the left face and arm lasting 3 hours, followed by bibleral fontal headache StrokerTLA/migraine? Stroke	th ERT, with substrate reduction
 A Long-torm Commitment: Treatment Era So it's a patient living with Pompe disease now for LOPD in an Evolving Treatment Era So it's a patient living with Pompe disease now for Lopdom Disease A Long-torm Commitment: Along-torm Commitment: So it's a patient living with Pompe Disease Vera 200 So it's really a nog-torm in the time here and any so it's really a long-term relationship between a patient and a treating physician. It all started in 2004, so it's really a long-term relationship between a patient and a treating physician. It all started in 2004, so it's really a long-term relationship between a patient and a treating physician. It all started in 2004, so it's really a long-term relationship between a patient and a treating physician. It all started in 2004, so it's really a stocke/TIA/migraine? Stocke/TIA/migraine? So it's a patient living with Pompe Disease (cont) So it's not a least 30 operated at the emergency department Living With Pompe Disease (cont) So it's not a least ad of course, there was 32 years old, presented at the emergency department, they did first line in the night a CT senset. 	 So it's a patient for at least 30 commitment: A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years age. relationship bet bilowed by biateral frontal headache Occurred 3 times within 2 months So it's a patient for at least 30 22 years old, department with her face and arm lasting 3 hours, followed by biateral frontal headache Occurred 3 times within 2 months So it's a patient for at least 30 22 years old, department with her face and arm lasting 3 hours, followed by biateral frontal headache So cocurred 3 times within 2 months So it's a patient with her face and her followed by biateral frontal headache So cocurred 3 times within 2 months So it's a migraine A differential. I lis this a migraine And therefore, department, the scan, and here ti dilatation of the scan, and he	more readily available. And we carefully about our treatment
 bink about multiple metrics, including importantly, patient-reported outcomes, as we make these treatment decisions and these treatment decisions. Thank you very much, and I'll pass to Professor Schoser. 55. Delivering Comprehensive Care for LOPD in an Evolving Treatment Era Bendits Booker, MD Treatment Era Bendits Booker, MD Treatment Era A Long-term Commitment: More Commitment of one of my patients. 56. A Long-term Commitment: More Commitment Living With Pompe Disease YEAR 2004 *Age 32 years: Numbres of the laft lace and arm lasting 3 hours, of Stoke/TLA/migraine? Stoke/TLA/migraine? Stoke/TLA/migraine? 57. A Long-term Commitment: A long-term commitment is a storke, of the laft and an masting of a hours. This was followed by a frontal headche. Episodes happened 3 times within 2 months. So that's we have a admitted. And of course, there was a differential. Is this a stroke-like situation? 57. A Long-term Commitment: Living With Pompe Disease (cont) Finance Commitment: Living With Pompe Disease (cont) Fin	 55. Delivering Comprehensive Care for LOPD in an Evolving Treatment Era So it's a patient for LOPD in an Evolving Treatment Era Bardit Schoer MD So it's a patient for at least 30 22 years ago. relationship bet physician. It all long time ago, 20 32 years old, department with for face and arm lasting 3 hours, followed by biateral fontal headache Occurred 3 times within 2 months Stoke/TIA/migraine? Stoke/TIA/migraine? Stoke/TIA/migraine? Stoke/TIA/migraine? Stoke/TIA/migraine? Stoke TIA/migraine? Stoke	patient preference as well is going
 55. Delivering Comprehensive Care for LOPD in an Evolving Treatment Era Delivering Comprehensive Care for LOPD in an Evolving Treatment Era Deniver and the set of the s	55. Delivering Comprehensive Care for LOPD in an Evolving Treatment Era All right, so god after these supe I'd like to thank come out here to think that's real to show you commitment of 56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. relationship bet physician. It all long time ago, 20 32 years old, department with her face and here followed by a later at interesting stroke/TIA/migraine? 57. A Long-term Commitment: A Long-term Commitment: A Datient Living With Pompe Disease • Occurred 3 times within 2 months So it's a patient for at least 30 22 years ago. relationship bet physician. It all long time ago, 20 32 years old, department with her face and here followed by a happened 3 tim why she was adr a differential. I ls this a migraine 57. A Long-term Commitment: A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A nd therefore, department, the scan, and here ti dilatation of the some calcificatii decided to go f angiography. A some white-ma	multiple metrics, including atient-reported outcomes, as we
56. A Long-term Commitment: A Patient Living With Pompe Disease 757. A Long-term Commitment: A Stroke/TIA/migraine? 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 5	56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. relationship bet physician. It all long time ago, 20 32 years old, department with her face and her followed by bilateral fontal headache 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont)	
 So it's a patient living with Pompe disease now for at least 30 years, and I got to know her 22 years ago. So it's really a long-term relationship between a patient and a treating physician. It all started in 2004, so it's really a long there with numbness of the left face and arm lasting 3 hours. followed by blateral frontal headache Ocoured 3 times within 2 months StrokerTu/migraine? StrokerTu/migraine?<!--</th--><th>56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 756. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 9 • Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache • Occurred 3 times within 2 months • Occurred 3 times within 2 months • Stroke/TIA/migraine? 32 years old, department wit her face and her followed by a happened 3 tim why she was adr a differential. I Is this a migraine 577. A Long-term Commitment: A Patient Living With Pompe Disease (cont) And therefore, department, the scan, and here to dilatation of the some calcificatii decided to go fa angiography. A some white-mate</th><th>per presentations? So, first of all,</th>	56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 56. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 756. A Long-term Commitment: A Patient Living With Pompe Disease So it's a patient for at least 30 22 years ago. 9 • Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache • Occurred 3 times within 2 months • Occurred 3 times within 2 months • Stroke/TIA/migraine? 32 years old, department wit her face and her followed by a happened 3 tim why she was adr a differential. I Is this a migraine 577. A Long-term Commitment: A Patient Living With Pompe Disease (cont) And therefore, department, the scan, and here to dilatation of the some calcificatii decided to go fa angiography. A some white-mate	per presentations? So, first of all,
 56. A Long-term Commitment: A Patient Living With Pompe Disease VEAR 2004 Age 32 years: Numbress of the left face and arm lasting 3 hours, followed by bilateral frontal headache Occurred 3 times within 2 months Stroke/TIA/migraine? Stroke/TIA/migraine? Stroke/TIA/migraine? Stroke	56. A Long-term Commitment: A Patient Living With Pompe Disease YEAR 2004 • Age 32 years: Numbress of the left face and arm lasting 3 hours, followed by bilateral frontal headache • Occurred 3 times within 2 months • Stroke/TIA/migraine? • Stroke/TIA/migraine? • Texe under • Stroke/TIA/migraine? • Texe • Stroke/TIA/migraine? • Texe • Stroke/TIA/migraine? • Texe • Occurred 3 time • Texe • Stroke/TIA/migraine? • Texe • Texe<	this early and listen to us. And I ally a major issue here. I also like
 A Patient Living With Pompe Disease YEAR 2004 Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache Occurred 3 times within 2 months Stroke/TIA/migraine? Stroke/TIA/migraine? The stroke/TIA/migraine? To measure at the emergency department with numbness of the left side of her face and her arm lasting for 3 hours. This was followed by a frontal headache. Episodes happened 3 times within 2 months. So that's why she was admitted. And of course, there was a differential. Is this a stroke-like situation? Is this a migraine or even a seizure situation? Stroke/TIA/migraine? 	 A Patient Living With Pompe Disease Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache Occurred 3 times within 2 months Stroke/TIA/migraine? Stroke/TIA/migraine? Stroke/TIA/migraine? To remember of the left face and arm lasting 3 hours, followed by an happened 3 time with her face and her followed by a happened 3 time why she was addres a differential. It is this a migraine? 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 8. Stroke (Content of the some calcification of the some c	f one of my patients.
 A Patient Living With Pompe Disease YEAR 2004 Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache Occurred 3 times within 2 months Stroke/TIA/migraine? Stroke/TIA/migraine? The stroke/TIA/migraine? To measure at the emergency department with numbness of the left side of her face and her arm lasting for 3 hours. This was followed by a frontal headache. Episodes happened 3 times within 2 months. So that's why she was admitted. And of course, there was a differential. Is this a stroke-like situation? Is this a migraine or even a seizure situation? Stroke/TIA/migraine? 	 A Patient Living With Pompe Disease Age 32 years: Numbness of the left face and arm lasting 3 hours, followed by bilateral frontal headache Occurred 3 times within 2 months Stroke/TIA/migraine? Stroke/TIA/migraine? Stroke/TIA/migraine? To remember of the left face and arm lasting 3 hours, followed by an happened 3 time with her face and her followed by a happened 3 time why she was addres a differential. It is this a migraine? 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 6. Stroke (Content of the pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 7. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 8. Stroke (Content of the some calcification of the some c	
 Stroke/TIA/migraine? Stroke/TIA/migraine?	 Stroke/TIA/migraine? <) years, and I got to know her So it's really a long-term etween a patient and a treating
 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term C	 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term C	presented at the emergency ith numbness of the left side of
 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term C	 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) 57. A Long-term Commitment: A Patient Living With Pompe Disease (cont) And therefore, department, the scan, and here the dilatation of the some calcification decided to go for angiography. A some white-mark 	a frontal headache. Episodes
A Patient Living With Pompe Disease (cont) A Patient Living With Pompe Disease (cont)	A Patient Living With Pompe Disease (cont)	dmitted. And of course, there was Is this a stroke-like situation?
CT Evan Brain Mar Brain Mar Br	CTGan Bilderar ditation angiogenty of the basis DW was unemarkable MAngiography Mangiography Stansis of left MCA Mangiography Stansis of left MCA Stansis of left MCA	ney did first line in the night a CT
* Blater distance sendocative (for basiliar mater issues	Cl Scan Michael M	tion. And in the morning, they for an MRI of the brain and an
aniwry Cartinae ar cartinae		atter changes were there, but
arranges Viery timy interestic residences. Data of the basilar arteria, what Science after any time, and the basilar arteria, what	CT computed i companety. DNI: difessione della i imagina, MCA: relative conduct aciny, MR: imagenetic resonance. MR: imagenetic resonance i imagina, Amazona dell' en al lineology. 2016 del 2012 Transport Control of B. Schware (MD).	ation of the basilar arteria, what
we call the megadolicho basilaris phenotype. And there was very low blood flow in this. And	And there was v	

Integrating New Therapies, Whole-Person Markers for Disease Monitoring, and Shared Decision-making Into Practice



But then, in the routine laboratory testing, they realized there were some more things going on with the patient. There's a mild proximal paresis that was not related to the situation that brought her to the emergency department, and there was also a CK elevation. And therefore, they referred the patient to me for a workup for the hyperCKemia. And what I realized, and hopefully the movie is starting, which was taken a bit later—there was already a classic waddling gait. So there was a Trendelenburg in that patient, proximal weakness, and also the arms were not as strong as they should be. And we had the opportunity, at a very early stage, to evaluate for GAA activity, but it took 8 weeks to get results. And so with a workup for hyperCKemia, we did something very classic. We used a muscle biopsy, and it looked for enzyme activity in the muscle tissue and also for the glycogen content. And, of course, it turned out it was a vacuolar myopathy. And all these types of things-the enzyme was reduced, the glycogen was high, and later on, with the sequencing of the GAA, we found a very classic Sanger sequencing. So this took more time than it does nowadays. It was a similar situation. And what we realized here was that even in the vasculature of these patients, in the muscle tissue, there was already a glycogen deposition. And that was later on, very well worked out. And we did know this information already. So it was not brand new. It was already there, if you look carefully at autoptic cases from the 1960s and 1970s and the angle. So one of the icons of Rochester University worked on this and already described parts of this. So it was all there. But it was, of course, neglected in a way. We were all focused on the metabolic part of the disease, but not on the multisystemic thing. And so therefore, we thought, it's good. And we published this in 2005. So it's really a long time

Integrating New Therapies, Whole-Person Markers for Disease Monitoring, and Shared Decision-making Into Practice

59.	<section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header>	So what happened? So as of 2023, this patient has received 400 standard-of-care infusions. So consider this—this is about 7 million US dollars for a patient over time, just on the enzyme. And here you see the decline. So in 2007 she was able to walk 385 meters in 6 minutes and the times up-and-go was 27. And also that WGMS grade was 3, but still the lung function was preserved, so that was all fine. And later on, you see, she was mainly sitting in a wheelchair and on a walker could just walk 60 meters and had a steady decline in all other motor functions. And on top there was also a big steep decline in the pulmonary function.
60.	<section-header><section-header><section-header><section-header><section-header><section-header><text><text><text></text></text></text></section-header></section-header></section-header></section-header></section-header></section-header>	Even in the walking you saw that there is a much prolonged and very severe disease now. This type of patient will never ever go to a clinical trial, she was never able based on the exclusion criteria to go on one of these phase 2 or even phase 3 trials. So therefore we had a long-term relationship and discussed several times what to do and what not to do. And in October she came up and said "Well, come on doctor, let's really try one of the new treatments." So I could never embark on any of the clinical trials, and now we have licensed drugs, so why should I not go and have a try? And finally I said "Yeah, why not?" So it's time to move on. And if there's still a functionally preserved tissue at risk, you can treat. So why shouldn't you switch a patient to one of the new enzymes? And that's very important. And that's what we did. And of course this is a very short-term follow-up. There's of course now no new change, but there were also no new side effects, but she was already commenting—and that's the point I'd like to make here—that "Well, this gave me back some new energy," "My fatigue is better, so I feel better, I even think I can walk a few steps more," and something else that happened to all of these patients, "I lost a little weight again." Because if your food intake stays the same, but your muscle capability to walk, to perform exercise declines, you gain weight easily, then you pick up a lot of extra pounds. And that is one of the issues here. And with this, at least it was for her the first time that she said, "Well something is changing." And what was the message here of this "you gave back hope". And hope is really transferring into also a functional commitment that she's now doing again all the

61.	What Are We Learning From This Patient's Comments?	testing that we are doing with her and also has the commitment to go very regularly now on the new treatment. And we will see what really happens to this patient in the long-term. But this is something very important. So adding a second type of ERT, a second-generation ERT is a very important decision that you have shared with the patient. So framing really, what are the expectations? What can we hope for together if I put you on a new treatment? And I had here the lucky situation that I put also a second-generation physician, treater physician on here. So I have here in the room Stefan Wenninger, a dear colleague of mine, and he is now committed and continues to work with the patient. And also this adds something. So it's the personal relationship in very chronic diseases that is so important. And you need to talk again and again to your patient. What is the exact right time point to switch? And of course you have all the knowledge, but the patient community, don't neglect them here in Pompe disease. They are very well aware of our clinical data and they know to read this right now. So therefore we need to keep them informed and try to get this message out together. And then it's not only hope, it's not only an emotional rescue, it also transfers really into a new treatment perspective of a very individualized basis, and that's very important.
	 We face a shift in Pompe disease therapy decision-making Availability of several therapy options and early diagnoses via NBS Growing role for SDM With a need for: Lay language material on the different therapeutic options Multidisciplinary team member input, including a physiotherapist, etc. Practical tools/PROs/digital devices Home infusion setting and monitoring Communication strategies to enhance SDM 	We have a lot of committed patients. We have a lot of committed first-, second-, and hopefully third-generation physicians who work with us. And also, of course, the industry is needed for this. We have now this early diagnosis, especially over here in the US, with the newborn screening. That also changes part of our
	NSS weden screwng. RRD pelen reported extorns SDM steed docsin making.	thinking. We have the growing role for this decision-making, and we need to create together some so-called lay language material that really is a fair-balance option for discussing all the different treatments we have. We also need to integrate a multidisciplinary team that really has a very holistic view on the patient. And then that's one of my hopes. And you listened to this yesterday morning, that we need this digitalizing next step in our patient-reported outcomes, and in all our clinical trial designs— we are still stuck in the last century with how we

62.	Polling Question Which of the following do you desire MOST to improve the treatment of your patients with Pompe disease? 1. Patient education materials on the different therapeutic options	are reporting. So 6MWT and all this, this is really testing from the past. We need to move on for our clinical trials, for new things, and that's here. And another thing that was perhaps not a big point in the US, but for all these treatments now in Europe, you have the option of home infusion. We know about the risk of this a bit, but anyhow, it's really a new way for the patients to have this treatment in their home. Also, they need to be monitored very safely. That's another thing we do not neglect over time. So we need to follow-up with them and know a communication pathway has a strategy to build up all these things we need to really use this type of approach. So now I also have a polling question for you. Which of the following do you desire most to improve the treatment of your patients with Pompe disease? There are 4 answers here. Patient education materials on the different
	 Methods for incorporating multidisciplinary team member input Digital devices for patient monitoring Methods for monitoring home infusions by the patient 	therapeutic options, methods in incorporating multidisciplinary team members, input digital devices for patient monitoring, or methods for monitoring home infusion by the patient himself. So again, who is voting for number 1? Good. Who is for number 2? Yeah, okay. Number 3? Yes, good. And methods for monitoring, home monitoring.
63.	<section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></section-header></section-header></section-header>	Okay, so let me wrap up our symposium. So we had 2 super speakers. They really brought up the new ideas we have for this disease. I think that's very good. We are diagnosing earlier. We have now 2 types of next-generation treatments. They are better at targeting skeletal muscle. We have still the caveat of the CNS. I think we need more treatment choices for the patients, and we have at least now 3 choices. So that's very good. But I guess we will have in the future only 2 of these ERTs, finally. Anyhow, we need to have better tools for the evaluation of our patients. So we need to integrate a bit more. Again, patient voices, PROs, and have more work on imaging. I think that is neglected. We still need to do more there, and we still have some minor limitations. I feel the clinical trial design is not really perfectly transferring into the real world. So that's a line up in a way, if we look at the preclinical data sets to the clinical trials and then clinical trials to the real-world situation. This is, unfortunately, always a decline in the efficacy of what we are doing and we need to rethink. So

	what is really the part where we have to do
	more work and where do we need extra
	thoughts? Young, fresh brains also needed
	there. And of course, we don't have this type of
	head-to-head study with our next-generation
	ERTs. But I think some part of this can be done
	in the registry studies that could really do some
	similar work on the 2 new enzymes. And then
	we will have more insights and perhaps even
	next year we can present the first results on this.